Augustine J. Lawlor's most recent trade in Cypherpunk Technologies Inc. was a trade of 22,500 Restricted Stock Units done . Disclosure was reported to the exchange on March 28, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Leap Therapeutics Inc | Augustine J. Lawlor | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 22,500 | 0 | - | - | Restricted Stock Units | |
| Leap Therapeutics Inc | Augustine J. Lawlor | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 22,500 | 27,586 (0%) | 0% | - | Common Stock | |
| Leap Therapeutics Inc | Augustine J. Lawlor | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.32 per share. | 28 Mar 2025 | 7,797 | 19,789 (0%) | 0% | 0.3 | 2,469 | Common Stock |
| Leap Therapeutics Inc | Augustine J. Lawlor | Chief Operating Officer | 13 Nov 2024 | 2,136 | 678,456 (2%) | 0% | 2.8 | 6,024 | Common Stock | |
| Leap Therapeutics Inc | Augustine J. Lawlor | Chief Operating Officer | 13 Nov 2024 | 2,136 | 0 | - | - | Warrant (Right to Buy) | ||
| Leap Therapeutics Inc | Augustine J. Lawlor | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Oct 2024 | 85,000 | 85,000 | - | - | Employee Stock Option (Right to Buy) | |
| Leap Therapeutics Inc | J. Augustine Lawlor | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2024 | 85,000 | 85,000 | - | - | Employee Stock Option (Right to Buy) | |
| Leap Therapeutics Inc | Lawlor J. Augustine | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2024 | 5,000 | 5,086 (0%) | 0% | - | Common Stock | |
| Leap Therapeutics Inc | Augustine J. Lawlor | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2024 | 5,000 | 0 | - | - | Restricted Stock Units | |
| Leap Therapeutics Inc | Augustine J. Lawlor | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 70,000 | 70,000 | - | - | Employee Stock Option (Right to Buy) | |
| Leap Therapeutics Inc | Augustine J. Lawlor | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 500,000 | 500,000 | - | - | Employee Stock Option (Right to Buy) | |
| Leap Therapeutics Inc | Augustine J. Lawlor | Chief Operating Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 225,000 | 225,000 | - | - | Restricted Stock Units | |
| Crescent Biopharma Inc | Augustine J. Lawlor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 5,839 | 24,573 (0%) | 0% | 0 | Common Stock | |
| Crescent Biopharma Inc | Augustine J. Lawlor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 14,000 | 14,000 | - | - | Stock Option (Right to Buy) | |
| Crescent Biopharma Inc | Augustine J. Lawlor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 5,542 | 18,734 (0%) | 0% | 0 | Common Stock |